Abstract
Samarium-153-lexidronam is a radiopharmaceutical used for pain palliation therapy in patients suffering from multilocular bone metastases. The postinjection residual of four pharmaceutical vials of 153Sm-lexidronam and one patient were investigated for contamination with other isotopes using high-resolution gamma spectroscopy. In the spectra besides the already known contaminants europium-154, 155Eu and 156Eu, europium-152 was discovered in vitro and also in vivo. 152Eu disintegrates with a half-life of 13.5years emitting a multitude of high energy photons. Due to these properties, it does not only affect radioactive waste management regarding e.g. the disposal of the postinjection residual, but also poses an additional dose burden to the patient and to third persons. In the postinjection residual a mean activity concentration of 10.4±1.1kBq europium-152 per GBq 153Sm was detected. 62days after isotope application, 15.8±4.0kBq of 152Eu were found within the patient. The lifetime effective dose to the patient from the europium impurities was determined using a multicompartment model. For 152Eu the effective dose was 2.1mSv/GBq 153Sm-lexidronam and the total effective dose from all impurities was 6.1mSv/GBq 153Sm-lexidronam. The total absorbed dose to third persons caused by the europium impurities was estimated as 0.6mGy/GBq 153Sm-lexidronam.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
